GlobeNewswire Inc.··NaCompass Therapeutics' CTX-8371 Shows 33% Response Rate in Checkpoint Inhibitor-Resistant Tumors
Compass Therapeutics reports promising Phase 1 data for CTX-8371 bispecific antibody in advanced cancer patients resistant to checkpoint inhibitors, with 33% response rate and no dose-limiting toxicities.
CMPXtriple-negative breast cancerPhase 1 clinical trial